Experimental CAR t therapy takes on solid tumors in first human trial

NCT ID NCT06193902

Recruiting now Disease control Sponsor: Leucid Bio Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe dose and check for any early signs that the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LEU011 (a type of immunotherapy using the patient's own immune cells, called CAR T cells, engineered to target NKG2D ligands on tumor cells)
What this could lead to: If successful, this could point toward a new treatment option for people with hard-to-treat solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, first-in-human trial with only 17 participants, so safety and effectiveness are not yet known. CAR T cell therapies can cause serious side effects like cytokine release syndrome or nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR, SOLID

Contacts and locations

Locations

Guy's and St Thomas' NHS Foundation Trust
RECRUITING

London, SE1 9RT, United Kingdom
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.